Protara Therapeutics, Inc.

NasdaqGM TARA

Protara Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD -2.13

Protara Therapeutics, Inc. Free Cash Flow Per Share is USD -2.13 for the Trailing 12 Months (TTM) ending September 30, 2024, a 29.16% change year over year. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

Protara Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -3.00, a -18.50% change year over year.
Protara Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -2.53, a 19.74% change year over year.
Protara Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -3.16, a 35.34% change year over year.
Protara Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -4.88.

Key data

Date	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)

NasdaqGM: TARA

Protara Therapeutics, Inc.

CEO	Mr. Jesse Shefferman
IPO Date	Oct. 22, 2014
Location	United States
Headquarters	345 Park Avenue South
Employees	26
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Key trends

Past 5 years